3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
8
Thoracic
3
Head & Neck
2
Breast
2
Sarcoma
1
Other solid neoplasm
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Mesothelioma
21
Mesothelioma, Malignant
18
Advanced Solid Tumor
17
Carcinoma, Non-Small-Cell Lung
15
Solid Tumor
14
Advanced Solid Tumors
13
Melanoma
12
Esophageal Neoplasms
10
Carcinoma, Renal Cell
10
Stomach Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
9
Uterine Cervical Neoplasms
8
Solid Tumors
8
Ovarian Neoplasms
8
Solid Tumor, Adult
7
Neoplasm Metastasis
7
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
6
Small Cell Lung Carcinoma
6
Breast Neoplasms
6
Pancreatic Neoplasms
5
Lung Neoplasms
5
Endometrial Neoplasms
5
Cholangiocarcinoma
5
Neoplasms
4
Locally Advanced or Metastatic Solid Tumors
4
Head and Neck Neoplasms
4
Advanced or Metastatic Solid Tumors
4
Urinary Bladder Neoplasms
3
Solid Tumor Malignancies
3
Interventions
pembrolizumab
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Immunotherapy
1
Hyperthermic Intraperitoneal Chemotherapy
1
Drug Therapy
1
Carboplatin
1
Biological Therapy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
pembrolizumab
×
Other solid neoplasm
×
Clear all
NCT05579366
2026-06-03
RAINFOL-01
Genmab
Phase 1/2
Recruiting
884 enrolled